IL13 and primary cutaneous T-cell non-Hodgkin lymphoma: Strategies to counteract this skewed cytokine milieu include targeting internal signaling with agents such as JAK inhibitors (e.g., ritlecitinib [38]) and blocking the IL-4 axis with IL-4Rα or IL-13 antibodies, which are currently under investigation in CTCL [28].